FDA Warns of Higher Death Risk With Pepaxto in Multiple Myeloma ...Middle East

Medscape - News
Following an accelerated approval earlier this year, analysis of data from an ongoing confirmatory trial has shown an increased risk of death with melphalan flufenamide (Pepaxto). Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Warns of Higher Death Risk With Pepaxto in Multiple Myeloma )

Apple Storegoogle play

Also on site :